Tunn Ren Tay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tunn Ren Tay has a total of 209 co-authors. Here are the top co-authors by number of shared publications:
- Mariko Siyue Koh
Singapore General Hospital
6 shared publications Anthony Yii
Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore
4 shared publicationsXue Ning Choo
Department of Respiratory and Critical Care Medicine Changi General Hospital Singapore City Singapore
4 shared publications- Anthony Chau Ang Yii
Department of Respiratory and Critical Care Medicine, Changi General Hospital, Singapore
3 shared publications - Mark Hew
Allergy, Asthma and Clinical Immunology Alfred Health Melbourne Victoria Australia
3 shared publications Yiong Huak Chan
Biostatistics Unit, Yong Loo Lin School of Medicine National University of Singapore Singapore City Singapore
3 shared publications
Latest Publications
- 15 September 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Development and validation of a pragmatic prediction model (READMIT score) for estimating 12-month hospital readmission in asthma
- 15 September 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Development and validation of a pragmatic prediction model (READMIT score) for estimating 12-month hospital readmission in asthma
- Open Access
- 4 December 2025
- Published by Elsevier in Clinical Medicine
- Vol. 26 (1) , 100540
Salmonella enteritidis meningitis in an immunocompetent adult
- 4 December 2025
- Published by Elsevier in Clinical Medicine
- Vol. 26 (1) , 100540
Open AccessSalmonella enteritidis meningitis in an immunocompetent adult
- 13 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (2) , 167-169
Direct and Indirect Pathways Between Patient, Health System and Socioeconomic Factors and Medication Adherence in Asthma
- 13 October 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (2) , 167-169
Direct and Indirect Pathways Between Patient, Health System and Socioeconomic Factors and Medication Adherence in Asthma
- Open Access
- 5 June 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 245, 108199
Ethnic variation in South East Asian patients with severe asthma: A first look at the Singapore Severe Asthma Registry (SSAR) and implications on clinical practice
- 5 June 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 245, 108199
Open AccessEthnic variation in South East Asian patients with severe asthma: A first look at the Singapore Severe Asthma Registry (SSAR) and implications on clinical practice
- 2 May 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (7) , 515-517
Treatable traits in an Asian difficult asthma cohort
- 2 May 2024
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 54 (7) , 515-517
Treatable traits in an Asian difficult asthma cohort
- 6 February 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (8) , 1613-1621
Interval change in fractional exhaled nitric oxide (FENO) reflects short-term change in adherence following electronic inhaler reminders
Background In asthma, suppression of fractional exhaled nitric oxide (FENO) is a marker of adherence in the short-term. The usefulness of FENO to indicate change in adherence in the longer term is unknown. The aims of this study were to determine the relationship between changes in adherence and corresponding changes in FENO over short (1 week) and long-term (3 month) periods. Methods After establishing initial ICS adherence using electronic inhaler monitor (EIM) devices, reminders were switched on for 1 week (‘short-term’) to optimize adherence. Reminders were then switched off and patients followed up after 3 months (‘long-term’). FENO was measured at the start and end of each period. Using linear regression, we analyzed change in FENO in relation to change in adherence. Results Forty-two patients contributed complete data for analysis. In the short-term, change in adherence was independently associated with change in FENO (β=-0.36, p = 0.036) even after adjusting for initial adherence and ICS dose. The higher the initial FENO, the greater the decline in FENO with improved adherence. This relationship between change in adherence and change in FENO was not observed in the long-term. Conclusion Change in adherence over 1 week following the use of EIM reminders independently predicted change in FENO. This relationship was not maintained at 3 months.
- 6 February 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (8) , 1613-1621
Interval change in fractional exhaled nitric oxide (FENO) reflects short-term change in adherence following electronic inhaler reminders
Background In asthma, suppression of fractional exhaled nitric oxide (FENO) is a marker of adherence in the short-term. The usefulness of FENO to indicate change in adherence in the longer term is unknown. The aims of this study were to determine the relationship between changes in adherence and corresponding changes in FENO over short (1 week) and long-term (3 month) periods. Methods After establishing initial ICS adherence using electronic inhaler monitor (EIM) devices, reminders were switched on for 1 week (‘short-term’) to optimize adherence. Reminders were then switched off and patients followed up after 3 months (‘long-term’). FENO was measured at the start and end of each period. Using linear regression, we analyzed change in FENO in relation to change in adherence. Results Forty-two patients contributed complete data for analysis. In the short-term, change in adherence was independently associated with change in FENO (β=-0.36, p = 0.036) even after adjusting for initial adherence and ICS dose. The higher the initial FENO, the greater the decline in FENO with improved adherence. This relationship between change in adherence and change in FENO was not observed in the long-term. Conclusion Change in adherence over 1 week following the use of EIM reminders independently predicted change in FENO. This relationship was not maintained at 3 months.
- 7 June 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (3) , 1-9
Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era
Objective: Short-acting bronchodilators for asthma and chronic obstructive pulmonary disease (COPD) exacerbations are commonly delivered by nebulizers although administration using metered dose inhaler with space chamber (MDI spacer) has been shown to be equally efficacious. There are few studies examining patients’ and healthcare providers’ attitudes on the two administration methods in adults. This study explores patients’ and healthcare providers’ attitudes on the use of nebulizer versus MDI spacer for acute asthma and COPD exacerbations in adults. Methods: Patients admitted for asthma or COPD exacerbations, doctors, and nurses in a university-affiliated hospital were surveyed from 1 April 2021 to 30 September 2021 regarding their views on the effectiveness, ease of use, preparation and administration, side effects, and infection risk of the two administration methods. Results: Ninety-nine patients, 103 doctors, and 650 nurses completed the survey. 60.6% of patients perceived nebulizer to be more effective. Patients who found nebulizer more comfortable were more likely to prefer nebulizer (OR 43.97, p = 0.01), while those who associated it with a greater infection risk were less likely to prefer nebulizer (OR 0.15, p = 0.03). 49.5% of doctors and 49.1% of nurses perceived nebulizer to be more effective, compared to 10.7% and 34.5%, respectively, for MDI spacer. Effectiveness and patient comfort influenced doctors’ and nurses’ preference for nebulizer while ease of preparation and administration influenced nurses’ preference only. Conclusions: Patients and healthcare providers perceived nebulizer to be more effective. Factors unique to each group influenced their preference for nebulizer.
- 7 June 2022
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (3) , 1-9
Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease exacerbation: attitudes of patients and healthcare providers in the COVID-19 era
Objective: Short-acting bronchodilators for asthma and chronic obstructive pulmonary disease (COPD) exacerbations are commonly delivered by nebulizers although administration using metered dose inhaler with space chamber (MDI spacer) has been shown to be equally efficacious. There are few studies examining patients’ and healthcare providers’ attitudes on the two administration methods in adults. This study explores patients’ and healthcare providers’ attitudes on the use of nebulizer versus MDI spacer for acute asthma and COPD exacerbations in adults. Methods: Patients admitted for asthma or COPD exacerbations, doctors, and nurses in a university-affiliated hospital were surveyed from 1 April 2021 to 30 September 2021 regarding their views on the effectiveness, ease of use, preparation and administration, side effects, and infection risk of the two administration methods. Results: Ninety-nine patients, 103 doctors, and 650 nurses completed the survey. 60.6% of patients perceived nebulizer to be more effective. Patients who found nebulizer more comfortable were more likely to prefer nebulizer (OR 43.97, p = 0.01), while those who associated it with a greater infection risk were less likely to prefer nebulizer (OR 0.15, p = 0.03). 49.5% of doctors and 49.1% of nurses perceived nebulizer to be more effective, compared to 10.7% and 34.5%, respectively, for MDI spacer. Effectiveness and patient comfort influenced doctors’ and nurses’ preference for nebulizer while ease of preparation and administration influenced nurses’ preference only. Conclusions: Patients and healthcare providers perceived nebulizer to be more effective. Factors unique to each group influenced their preference for nebulizer.
- 7 October 2021
- Published by Wiley in Respirology
- Vol. 27 (1) , 48-55
Laryngeal hypersensitivity and abnormal cough response during mannitol bronchoprovocation challenge
Background and objective: Inhalational challenge with dry mannitol powder may potentially induce cough by two mechanisms: airway bronchoconstriction or laryngeal irritation. This prospective observational study investigated laryngeal and bronchial components of cough induced by mannitol challenge.Methods: We recruited consecutive patients referred for clinical mannitol challenge. The Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) was administered. Throughout testing, coughs were audio‐recorded to derive a cough frequency index per time and dose of mannitol. Relationships between cough indices, laryngeal hypersensitivity and bronchial hyperresponsiveness (BHR) were examined. Participants were classified by cough characteristics with k‐means cluster analysis.Results: Of 90 patients who underwent challenge, 83 completed both the questionnaire and challenge. Cough frequency was greater in patients with abnormal laryngeal hypersensitivity (p = 0.042), but not in those with BHR. There was a moderate negative correlation between coughs per minute and laryngeal hypersensitivity score (r = −0.315, p = 0.004), with lower LHQ scores being abnormal. Cluster analysis identified an older, female‐predominant cluster with higher cough frequency and laryngeal hypersensitivity, and a younger, gender‐balanced cluster with lower cough frequency and normal laryngeal sensitivity.Conclusion: Cough frequency during mannitol challenge in our cohort reflected laryngeal hypersensitivity rather than BHR. Laryngeal hypersensitivity was more often present among older female patients. With the incorporation of cough indices, mannitol challenge may be useful to test for laryngeal hypersensitivity as well as BHR.
- 7 October 2021
- Published by Wiley in Respirology
- Vol. 27 (1) , 48-55
Laryngeal hypersensitivity and abnormal cough response during mannitol bronchoprovocation challenge
Background and objective: Inhalational challenge with dry mannitol powder may potentially induce cough by two mechanisms: airway bronchoconstriction or laryngeal irritation. This prospective observational study investigated laryngeal and bronchial components of cough induced by mannitol challenge.Methods: We recruited consecutive patients referred for clinical mannitol challenge. The Newcastle Laryngeal Hypersensitivity Questionnaire (LHQ) was administered. Throughout testing, coughs were audio‐recorded to derive a cough frequency index per time and dose of mannitol. Relationships between cough indices, laryngeal hypersensitivity and bronchial hyperresponsiveness (BHR) were examined. Participants were classified by cough characteristics with k‐means cluster analysis.Results: Of 90 patients who underwent challenge, 83 completed both the questionnaire and challenge. Cough frequency was greater in patients with abnormal laryngeal hypersensitivity (p = 0.042), but not in those with BHR. There was a moderate negative correlation between coughs per minute and laryngeal hypersensitivity score (r = −0.315, p = 0.004), with lower LHQ scores being abnormal. Cluster analysis identified an older, female‐predominant cluster with higher cough frequency and laryngeal hypersensitivity, and a younger, gender‐balanced cluster with lower cough frequency and normal laryngeal sensitivity.Conclusion: Cough frequency during mannitol challenge in our cohort reflected laryngeal hypersensitivity rather than BHR. Laryngeal hypersensitivity was more often present among older female patients. With the incorporation of cough indices, mannitol challenge may be useful to test for laryngeal hypersensitivity as well as BHR.
- Open Access
- 10 November 2020
- Published by Taylor & Francis in Journal of Asthma
- Vol. 59 (1) , 189-199
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
To evaluate the cost-effectiveness of mepolizumab added to standard of care (SOC) compared with SOC alone among patients with severe uncontrolled eosinophilic asthma in the Singapore setting. A Mar...
- 10 November 2020
- Published by Taylor & Francis in Journal of Asthma
- Vol. 59 (1) , 189-199
Open AccessAssessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
To evaluate the cost-effectiveness of mepolizumab added to standard of care (SOC) compared with SOC alone among patients with severe uncontrolled eosinophilic asthma in the Singapore setting. A Mar...